Conopeptides
OwnerBruce Furie, Barbara C. Furie +3inventors
InventorsBruce Furie, Barbara C. Furie, Johan Stenflo, Alan C. Rigby, Peter Roepstorff
Life of this patent
Estimating the term…
Abstract
Substantially pure conopeptides containing γ-carboxyglutamic acid are disclosed.
Claims14
A substantially pure peptide having the amino acid sequence:
- Asp Val Pro X1 Ile Val Leu X2 Phe Met Cys Pro Val Ile Cys Gly Asn Gly Phe Gly X3 Glu Tyr Cys Asn Cys Thr (SEQ ID NO:1), wherein each of X1, X2, and X3 is independently selected from Glu and Gla, provided that at least one of X1, X2, and X3 is Gla.
A substantially pure peptide having the amino acid sequence:
- Ser Cys Asp Ser X4 Phe Ser Ser X5 Phe Cys X6 Arg Pro X7 X8 Ser Cys Ser Cys Ser Thr His Thr Cys Cys His Trp Ala Arg Arg Asp Gln Cys Met Lys Pro Gln Arg Cys Ile Ser Ala Gln Lys Gly Asn (SEQ ID NO:2), wherein each of X4, X5, X6, X7, and X8 is independently selected from Glu and Gla, provided that at least one of X4, X5, X6, X7, and X8 is Gla.
A substantially pure peptide having the amino acid sequence:
- Arg X9 X10 Cys Cys Ser Asp Pro Arg Cys Asn Ser Ser His Pro X11 Leu Cys Gly (SEQ ID NO:3), wherein X9 is Pro or OHP and each of X10 and X11 is independently selected from Glu and Gla, provided that at least one of X10 and X11 is Gla.
A substantially pure peptide having the amino acid sequence:
- Gly Cys Asn Asn Ser Cys Gln X12 His Ser Asp Cys X13 Ser His Cys Ile Cys Thr Phe Arg Gly Cys Gly Ala Val Asn (SEQ ID NO:4), wherein each of X12 and X13 is independently selected from Glu and Gla, provided that at least one of X12 and X13 is Gla.
A substantially pure peptide having the amino acid sequence:
- Cys Ile Pro Gla Gly Ser Ser Cys Ser Ser Ser Gly Ser Cys Cys His Lys Ser Cys Cys Arg Trp Thr Cys Asn Gln Pro Cys Leu (SEQ ID NO:5).
A substantially pure peptide having the amino acid sequence:
- Gly Met X14 Gly X15 Cys Lys Asp Gly Leu Thr Thr Cys Leu Ala X16 Ser X17 Cys Cys Ser X18 Asp Cys X19 Gly Ser Cys Thr Met X20 (SEQ ID NO:6), wherein each of X14 and X20 is independently selected from Trp and BrW, each Of X15, X17, X18, and X19 is independently selected from Glu and Gla, provided that at least one of X15, X17, X18, and X19 is Gla, and X16 is Pro or OHP.
A substantially pure peptide having the amino acid sequence:
- X21 Cys Cys X22 Asp Gly X23 Cys Cys Thr Ala Ala X24 (SEQ ID NO:7), wherein each of X21 and X22 is independently selected from Glu and Gla, provided that at least one of X21 and X22 is Gla, X23 is Trp or BrW, and X24 is Pro or OHP.
A substantially pure peptide having the amino acid sequence:
- Ser Cys Ser Asp Asp Trp Gln Tyr Cys Gla Ser X25 Thr Asp Cys Cys Ser X26 Asp Cys Asp Val Val Cys Ser (SEQ ID NO:8), wherein X25 is Pro or OHP and X26 is Trp or BrW.
A substantially pure peptide having the amino acid sequence:
- Ala X27 Cys His X28 Cys X29 Phe Gla Tyr (SEQ ID NO:9), wherein X27 is Trp or BrW and each of X28 and X29 is independently selected from Pro and OHP.
A substantially pure peptide having the amino acid sequence:
- Asn Cys Ser Asp Asp Trp Gln Tyr Cys Gla Ser X30 Ser Asp Cys Cys Ser X31 Asp Cys Asp Val Val Cys Ser (SEQ ID NO:10), wherein X30 is Pro or OHP and X31 is Trp or BrW.
A substantially pure peptide having the amino acid sequence:
- Leu Cys X32 Asp Tyr Thr X33 X34 Cys Ser His Ala His X35 Cys Cys Ser X36 Asn Cys Tyr Asn Gly His Cys Thr Gly (SEQ ID NO:11), wherein each of X32 and X34 is independently selected from Pro and OHP, and each of X33 and X35 is independently selected from Glu and Gla, provided that at least one of X33 and X35 is Gla, and X36 is Trp or BrW.
Dependencies are inferred from the claim text.